Literature DB >> 15455183

Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.

J M Liu1, H Y Zhao, G Ning, Y J Zhao, Y Chen, Zh Zhang, L H Sun, M-Y Xu, J L Chen.   

Abstract

The correlations between the serum levels of OPG, RANKL with age, menopause, bone markers, and bone mineral densities (BMDs) at the lumbar spine and proximal femur were studied in 504 pre- and postmenopausal Chinese women aged 20-75 years. We found that age was positively and negatively correlated with serum concentrations of OPG (r = 0.442, P < 0.001) and RANKL (r = -0.263, P < 0.001), respectively. Compared with premenopausal women, postmenopausal women showed higher serum OPG levels (107.6 +/- 3.0 vs 72.0 +/- 1.8 pg/ml, P < 0.001), lower serum RANKL concentrations (4.7 +/- 0.4 vs. 5.8 +/- 0.3 pg/ml, P < 0.001) and RANKL/OPG ratios (0.045 +/- 0. 004 vs. 0.099 +/- 0.008, P < 0.001). Neither serum levels of OPG nor RANKL or RANKL/OPG ratio correlated with BMDs after adjustment of age and menopause. They also showed no differences among normal, osteopenic and osteoporotic postmenopausal women. Serum levels of OPG were positively correlated with urinary excretion of NTx (r = 0.1453, P = 0.006). Serum levels of RANKL (r = -0.1928, P < 0.001) and RANKL/OPG ratio (r = -0.1303, P = 0.013) were inversely correlated with serum concentrations of OC. In multiple regression analysis, up to 20% variance (R(2) = 0.106-0.224) of the OPG-RANKL system in peripheral circulation can be explained by age, menopause and bone markers. These results suggest that although serum OPG and RANKL concentrations were unrelated with BMDs, the age- and menopause- dependent changes of serum OPG and RANKL might be a protective mechanism against the accelerated bone loss in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455183     DOI: 10.1007/s00223-004-0007-2

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  24 in total

Review 1.  Osteoporotic fractures in Asia: risk factors and strategies for prevention.

Authors:  Jian-min Liu; Guang Ning; Jia-lun Chen
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

2.  Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.

Authors:  Leonid Gibiansky; Liviawati Sutjandra; Sameer Doshi; Jenny Zheng; Winnie Sohn; Mark C Peterson; Graham R Jang; Andrew T Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

3.  Estrogens and androgens inhibit association of RANKL with the pre-osteoblast membrane through post-translational mechanisms.

Authors:  Anthony Martin; Jiali Yu; Jian Xiong; Aysha B Khalid; Benita Katzenellenbogen; Sung Hoon Kim; John A Katzenellenbogen; Suchinda Malaivijitnond; Yankel Gabet; Susan A Krum; Baruch Frenkel
Journal:  J Cell Physiol       Date:  2017-05-11       Impact factor: 6.384

4.  Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.

Authors:  Nicholas G Angelopoulos; Anastasia Goula; Eugenia Katounda; Grigorios Rombopoulos; Victoria Kaltzidou; Dimitrios Kaltsas; Sophia Malaktari; Vassilis Athanasiou; George Tolis
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

5.  Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.

Authors:  Liviawati Sutjandra; Rachelle D Rodriguez; Sameer Doshi; Mark Ma; Mark C Peterson; Graham R Jang; Andrew T Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

6.  Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.

Authors:  J Coulson; L Bagley; Y Barnouin; S Bradburn; G Butler-Browne; H Gapeyeva; J-Y Hogrel; T Maden-Wilkinson; A B Maier; C Meskers; C Murgatroyd; M Narici; M Pääsuke; L Sassano; S Sipilä; N Al-Shanti; L Stenroth; D A Jones; J S McPhee
Journal:  Osteoporos Int       Date:  2017-06-05       Impact factor: 4.507

7.  Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle.

Authors:  Bruno Mozzanega; Salvatore Gizzo; Daniela Bernardi; Luigi Salmaso; Tito Silvio Patrelli; Roberto Mioni; Livio Finos; Giovanni Battista Nardelli
Journal:  J Bone Miner Metab       Date:  2013-03-12       Impact factor: 2.626

8.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

9.  Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.

Authors:  H Uemura; T Yasui; Y Miyatani; M Yamada; M Hiyoshi; K Arisawa; M Irahara
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

10.  Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.

Authors:  H-Y Zhao; J-M Liu; G Ning; Y-J Zhao; Y Chen; L-H Sun; L-Z Zhang; M-Y Xu; J-L Chen
Journal:  Osteoporos Int       Date:  2007-08-17       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.